AIMS: Robust prognostic markers for ductal carcinoma in situ (DCIS) of the breast require high reproducibility and thus low interobserver variability. The aim of this study was to compare interobserver variability among 13 pathologists, in order to enable the identification of robust histopathological characteristics. METHODS AND RESULTS: One representative haematoxylin and eosin-stained slide was selected for 153 DCIS cases. All pathologists independently assessed nuclear grade, intraductal calcifications, necrosis, solid growth, stromal changes, stromal inflammation, and apocrine differentiation. All characteristics were assessed categorically. Krippendorff's alpha was calculated to assess overall interobserver concordance. Cohen's kappa ...
BACKGROUND: There is no consensus agreement regarding optimal management of locally excised ductal c...
PURPOSE: To compare the histological grades of screen detected and non-screen detected ductal carcin...
Abstract Background Previously, 50% of patients with breast ductal carcinoma in situ (DCIS) had more...
AIMS: Robust prognostic markers for ductal carcinoma in situ (DCIS) of the breast require high repro...
Histopathological assessment of ductal carcinoma in situ, a nonobligate precursor of invasive breast...
Histopathological assessment of ductal carcinoma in situ, a nonobligate precursor of invasive breast...
Purpose For optimal management of ductal carcinoma in situ (DCIS), reproducible histopathological as...
OBJECTIVES: Since most patients with ductal carcinoma in situ (DCIS) of the breast are treated upon ...
The prognostic value of cytonuclear grade in ductal carcinoma in situ (DCIS) is debated, partly due ...
Purpose: A considerable part of ductal carcinoma in situ (DCIS) lesions may never progress into inva...
BACKGROUND: Diagnostic agreement among pathologists is 84% for ductal carcinoma in situ (DCIS). Stud...
Ductal carcinoma in situ (DCIS) is a heterogeneous malignant condition of the breast with an excelle...
Ductal carcinoma in situ (DCIS) is a heterogeneous, unicentric precursor of invasive breast cancer, ...
Background: There is no consensus agreement regarding optimal management of locally excised ductal c...
Objectives: Ductal carcinoma in situ (DCIS) is a non-invasive lesion of an increasing clinical impor...
BACKGROUND: There is no consensus agreement regarding optimal management of locally excised ductal c...
PURPOSE: To compare the histological grades of screen detected and non-screen detected ductal carcin...
Abstract Background Previously, 50% of patients with breast ductal carcinoma in situ (DCIS) had more...
AIMS: Robust prognostic markers for ductal carcinoma in situ (DCIS) of the breast require high repro...
Histopathological assessment of ductal carcinoma in situ, a nonobligate precursor of invasive breast...
Histopathological assessment of ductal carcinoma in situ, a nonobligate precursor of invasive breast...
Purpose For optimal management of ductal carcinoma in situ (DCIS), reproducible histopathological as...
OBJECTIVES: Since most patients with ductal carcinoma in situ (DCIS) of the breast are treated upon ...
The prognostic value of cytonuclear grade in ductal carcinoma in situ (DCIS) is debated, partly due ...
Purpose: A considerable part of ductal carcinoma in situ (DCIS) lesions may never progress into inva...
BACKGROUND: Diagnostic agreement among pathologists is 84% for ductal carcinoma in situ (DCIS). Stud...
Ductal carcinoma in situ (DCIS) is a heterogeneous malignant condition of the breast with an excelle...
Ductal carcinoma in situ (DCIS) is a heterogeneous, unicentric precursor of invasive breast cancer, ...
Background: There is no consensus agreement regarding optimal management of locally excised ductal c...
Objectives: Ductal carcinoma in situ (DCIS) is a non-invasive lesion of an increasing clinical impor...
BACKGROUND: There is no consensus agreement regarding optimal management of locally excised ductal c...
PURPOSE: To compare the histological grades of screen detected and non-screen detected ductal carcin...
Abstract Background Previously, 50% of patients with breast ductal carcinoma in situ (DCIS) had more...